Bladder rupture after pembrolizumab immunotherapy for bladder cancer: a case report

Pembrolizumab is a promising checkpoint inhibitor for advanced urothelial carcinoma. Like other immunotherapies, it can cause rare immune-related adverse events. The spontaneous rupture of the urinary bladder after the intravenous injection of pembrolizumab is rare and has not been reported. Here, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Badheeb, Ahmed, Alkhanbashi, Omar, Rakrouki, Slah, Mahmood, Tahir, Alqannas, Mashhoor, Badheeb, Mohamed, Ahmed, Faisal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379440/
https://www.ncbi.nlm.nih.gov/pubmed/36034031
http://dx.doi.org/10.11604/pamj.2022.42.98.33911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379440/
https://www.ncbi.nlm.nih.gov/pubmed/36034031
http://dx.doi.org/10.11604/pamj.2022.42.98.33911

Ejemplares similares